Blueprint Medicines (BPMC) PT Raised to $59 at Morgan Stanley
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Price: $129.46 --0%
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Join SI Premium – FREE
Morgan Stanley analyst Michael Ulz raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $59.00 (from $55.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Golar LNG Ltd. (GLNG) PT Raised to $70 at BTIG
- Cellebrite (CLBT) PT Lowered to $15 at TD Cowen
- Asia Vital Components Co Ltd (3017:TT) PT Raised to NT$4,250 at Macquarie
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
